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For over five decades minor histocompatibility (mH) antigens
have contmued to fascmate immimologists, mainly because of
their minor but distinct role in transplantation but no less
because of their as yet unknown nature In the 1970s lt
became evident that mH antigens were recognized in a MHC
restncted fashion, an important feature which was poorly
understood at that time Through the innovative work on the
MHC class I crystals, significant insight into the nature of mH
antigens as MHC-bound peptides has recently been obtained
Thanks to extensive munne and human studies, more knowl-
edgc, though still the tip of the lceberg, has been gathered
with regard to the role of mH antigen specific cytotoxic Τ cell
(CTL) and helper Τ (Th) cell responses in bone marrow
transplantation
In this review, we have restncted ourselves to the discus-
sion of two main aspects of human mH antigen specific CTLs,
the first being their long debated mechamstic mvolvement in
the pathogenesis of graft versus host disease (GvHD) after
HLA-idenücal bone marrow transplantation (BMT), the sec-
ond being the molecular nature of the cell surface epitopes
seen by these MHC class I restncted mH antigen specific
CTLs
History and definition of mH antigens
At the begmning of this centui y, Little and Tyzzer1 observed
that the rejection of tumour grafts by mbred strains of mice
was regulated by a family of 'ndependently segregating genes
The Identification of Single loci responsible for tumour graft
rejection became possible in 1940 when Snell outlmed a
procedure for the production of so-called congemc-resistant
mouse strains Mice of these congemc strains rejected tumour
grafts from mbred partners as a result of ι genetic dispanty
for one short donor-strain derived chromosomal Segment,
thus said to contam a 'histocompatibility' (H), locus 2 One of
the 13 Η loci onginally identified by Snell was the H-2 locus,
which was later named the major histocompatibility complex
(MHC) This name resulted from the observation that the
speed with which tumour graft rejection was induced by
dispanty at these histocompatibility loci vaned greatly, and
that the H-2 locus was amongst the strongest (major) ones
All other histocompatibility loci found to induce tumour graft
rejection were grouped under the complementary name of
minor hislocompatibility (mH) loci Bailey contmued the
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search for mH loci by usmg skm mstead of tumour graft
rejection as a more sensitive histogemc measure for mH
mcompatibihty
In addition to in vivo tumour and skin graft rejectioii, histo-
mcompabitility at these mH loci was found to induce Τ cell
responses which could be analyzed m vitro Bevan3 and
Simpson4 were the first to describe cytotoxic Τ cell (CTL)
responses measurable in a cell lympholysis (CML) assay after
in vivo pnming across multiple or Single mH dispanties
These donor stram reactive CTLs were found to recognize
the lmmumzing mH antigen m a MHC class I restncted
fashion and provided a powerful tool for detailed in vitro
analysis of mH antigens Over 40 mH loci have been defined
using Snell's and Bailey's congemc mouse strams, all sharing
the common features of mducing skm or tumour graft rejec-
tion and of MHC restncted in vitro CTL responses (reviewed
in5)
In man, the existence of mH loci became evident with the
discovery of the human analogue of the munne MHC the
human leucocyte antigens (HLA) by Dausset, Payne and Van
Rood 6 Kidney and bone marrow grafting between mdivid-
uals with genetic identity at the HLA genes was still observed
to result in graft rejection or graft-versus-host disease
(GvHD) (reviewed in 7 ) Unhke the Situation in the mouse,
the Single loci responsible for these immune responses could
not be isolated via histogenetic methods Instead, human mH
loci were identified with Τ cell populations obtained after in
vivo grafting across multiple mH incompatibilities By gen-
eratmg MHC class I restncted CTL hnes from such ιη-
dividuals, the in vitro definition of Single human mH gene
products commenced 7 Thus far, the efforts of several m-
vestigators have led to the Identification of a small number of
human mH antigens.
Over the last few years the understanding of the nature of
mH gene products has rapidly increased With these msights,
the notion grew that the name of minor histocompatibility
antigens, first mtroduced 44 years ago to describe transplanta-
tion phenomena, might raise false suggestions with respect to
their nature First, the term minor mrplies relatively 'not
important' In the chmcal setting of organ and bone marrow
transplantation between HLA-identical, mH antigen mis-
matched individuals, these antigens are capable of mducing
vigorous immune responses leading to graft rejection or graft-
versus-host disease. Secondly, the name minor histocompati-
bility suggests we are dealmg with a group of related loci
forming the counterpart of the complex of major histocompa-
tibility genes However, whereas the MHC gene products
form a homogeneous group with respect to function, so far no
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Information IS available on a potential common function of
mH proteins Thirdly, in contrast to the term major histo-
compatibility antigen, which refers to an immunogenic Irans-
membrane glycoprotein, lt is indicated that no molecule exists
to which the term mmor histocompatibility antigen could
refer With the forthcommg molecular Identification of the
epitopes seen by mH antigen specific Τ cells, and their
mtracellular sources, more specific and functionally appro-
pnate names will undoubtedly manifest themselves in the
coming years
Human mH antigens
Genetics and polymorphism
Human mH antigens have been defined by means of MHC
restncted Τ cells to be obtamed from individuals pnmed in
vivo with HLA compatible cells Both MHC class II restncted
prohferative and MHC class I restncted cytotoxic Τ cell
clones have been used to define mH antigens Descnption of
CTL populations observed after pnmmg after pregnancy,
blood transfusion, kidney grafting, and especially after HLA-
ldentical bone marrow grafting (reviewed in 7 ) , has been very
common Alas, the elaborate task of characterr/ation of the
epitopes recogmzed, m terms of population frequencies,
segregation patterns and allehsm, has only been undertaken
for six mH antigens (1 e W-l8 and HA-1 to HA 59) of the
small number of mH antigemc CTL epitopes reported so far
(Table 1)
As yet no data are available on the total number ot loci
encodmg Τ cell defined human mH antigens The mcidence of
Τ cell mediated immune reactions in 45% of recrpients of
HLA genotypically identical bone marrow10 suggests that
incompatibilily for at least one non-HLA locus is very
common This high probabihty of mH dispanty, even
between siblings, might theoretically result from a high
number of alleles per locus (discussed below) and/or a high
number of mH loci in the human genome
The locations of human mH genes which encode CTL
defined products are not known, with the exception of the
gene encodmg the male-specific antigen H-Y Simpson et al
pinned the H-Y encodmg gene on the long arm of the Υ
chromosome," thereby separatmg Η from the testis determm-
mg gene, TDF De Gast used polymorphic blood genetic
makers with known gene locahzation to locahze the non-
MHC loci responsible for GvHD after related HLA-identical
BMT Dispanty for the markers rhesus, MNSs and acid
phosphatase, located on chromosome 1, 4 and 5 respectively,
correlated with mcreased chromc GVHD (see 7 ) Although a
direct parallel between this observation and the location of
CTL-defmed mH loci is not possible, these data would be
compatible with the concept that human mH loci, as in the
mouse, are located on several chromosomes
The population frequency of mH alleles represents a
functionally relevant parameter which could be studied in
man Extensive analysis of the mH antigens W-l,8 and HA 1,
HA-2, HA-3, HA-4, and HA 5'1 has indicated phenotype
frequencies of 80,69, 95, 88,16 and 7%, respecüvely, within a
panel of unrelated individuals all expressing the required
MHC class I restriction molecule The contrasting very low or
very high frequencies of these human mH phenotypes is
compatible with the indicated frequencies of murme alleles 12
The question of how many alleles exist for each locus remains
to be settled The fact that in vivo pnming is required to
define any given mH antigen forms an mtnnsic complication
in the study of potential allelic products, since pnming m any
HLA-identical transplantation settmg is um-directional Van
Eis et al made the observation that none of a panel of 100
HLA-A2 expressing individuals ever coexpressed the three
HLA-A2 restncted mH antigens HA-1, HA-4 and HA-5
However, the numbers did not suffice to prove or disprove
whether HA-1, HA-4 and HA-5 might represent allelic
products of the same locus 9
Whereas the mH loci of congemc mice were defined as
mdependently segregating umts, the CTL-based defimtion of
human mH antigens does not require this Where analyzed,
mH phenotypes were found to be mhented and not to
spontaneously arise or disappear withm famihes 7 8 However,
the MHC class I restncted recogmtion of mH antigens
provided a structural hmitation confoundmg thorough segre-
gation analysis in famihes Both Zier et al13 and our own
group14 showed that this frustratmg prerequisite could be
circumvented by msertmg the missmg MHC molecule by
membrane fusion or gene transfection into cells of family
members naturally lackmg the restriction molecule Using
this techmque lo generate complete HLA-A2 expressing
famihes, we showed that the segregation patterns of the mH
antigens HA-1, HA 2, HA-4 and HA-5 are compatible with
them being products of smgle genes mhented in a Mendehan
fashion (Schreuder et al, in press)
Τ cell response to mH antigens
While MHC antigens can be recogmzed by Β and Τ lympho-
cytes, responses to mH antigens appear predominantly Τ cell
mediated Though some reports exist on putative mH antigen
specific antibodies, mainly towards the male-specific antigen
H-Y, these antisera have proved to be weak or nonspecific
The only solid exception is the H-3 encoded beta 2 micro-
globulm (ß2m) molecule which induces a strong and specific
antibody response 20 The mability to measure strong Β cell
responses to mH antigens and the apparent exception of the
ß2m molecule can nowadays be explained by the knowledge
that mH antigemc Τ cell epitopes, with the exception of ß2m,
are most probably small peptides as will be discussed later
Τ cell responses to mH antigens in man and mouse are
charactenzed by three main features First, in vitro detection
of mH antigen specific Τ cells in general requires an in vivo
primmg phase followed by an in vitro boosting phase Sec-
ondly, Τ cells definmg mH antigens are MHC restncted An
exception to this rule is the murme mH antigen Mls (now
known to be a retroviral product21) which is seen in the
context of any I-A and I-E class II molecule Α third common
and charactenstic feature, so far only proven to regulate Τ
cell responses to murine mH antigens, is the phenomenon of
immunodommance
In vivo pnming
In vitro coculture of unpnmed penpheral blood leukocytes
(PBL) or spieen cells of mH antigen disparate donors, does
not result in measurable prohferation in mixed lymphocyle
reactions (MLR), cytotoxicity in CML assays or lymphokine
production Α low frequency of mH antigen specific CTL
precursors is commonly thought to underlie this phenom-
enon
 2 2
 Another explanation might bc that the antigen pre-
senting cells (APC) present in vivo are better equipped to
present mH antigens than the spieen cells and penpheral
blood leucocytes used in vitro In fact, in those exceptional
cases where investigators did observe pnmary in vitro respon-
ses to mH antigens, unusual sources of stimulator cells such as
leukaemic cells,23 epidermal cells24 or bone marrow cells25
were employed To fully understand the role of distinct APC
in the mduction of mH CTL responses, the processmg route
and requirements of mH antigens should be known, as will be
discussed later on CTL responses to viral antigens show a
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Table 1 Human mH antigens defined by MHC class
Defining CTL population(s)
Code #a Dispanty Pnming
I restncted
Clonalc
CTL clones
HLA-
restnction
Coae
mH antigen
Frequencyb Sejgregation Ref
—
A10 4
NH-5 2
NH-5 4
1R35
5W4
R26
A42
3HA15
5H17
5HO11
5G30
5W27
cl21
cl6
—
l d
4"
2
2
1
3
2
4
2
3
1
2
2
1
HLA-id
sibhng
HLA-id
sibhng
HLA-id
sibhng
HLA-id
sibhng
HLA-id
sibhng
9
HLA-id
sibhng
?
H L A i d
sibhng
HLA-id
sibhng
HLA-id
sibhng
HLA-id
sibhng
HLA-id
sibhng
HLA-id
sibhng
H L A i d
sibhng
BMT/
host —* graft
BMT/
host -» graft
kidney graft
kidney graft
BMT/
host -> graft
blood
transfusions
BMT/
host -»graft
blood
transfusions
BMT/
graft -> host
BMT/
graft -»host
BMT/
graft —»host
BMT/
graft —* host
BMT/
graft -+ host
BMT/
graft -» host
BMT/
graft -+ host
B7
B7/B27
B35
B38
A21
B7
B60
AI
A21
A 2 1
AI
A 2 1
A 2 1
B7
B7
Wl
—
hmH
A-1
hmH
A-2
Η Υ
Η Υ
Η-Υ
Η-Υ
ΗΑ-1
ΗΑ-2
Η Α 3
ΗΑ-4
ΗΑ-5
ΗΑ-6
ΗΑ-7
110/141
7/9
6/6
3/4
100/100
(m)
60/60 (m)
45/45 (m)
32/32 (m)
69/100
95/100
88/100
16/100
7/100
15/16
13/15
Mendehan
Single gene
nt
nt
nt
Y-chrom
Υ chrom
Y-chrom
Υ chrom
Mendehan
Single gene
Mendehan
Single gene
Mendehan
Single gene
Mendehan
Single gene
nt
nt
nt
8
15
16
16
17
17
18
7,9
7,9
7,9
7,9
7,9
19
19
a
number of CTL clones with identical panel recogmtion,
b(number of positive ind /total number of unrelated md tested, all restriction antigen+),
c
monoclonahty confirmed by TCR-rearrangement patterns,
dthree more clones were descnbed with B7 and/or B27 restncted activity on a panel of nme,
e
one more B35 restncted clone analyzed on a panel of four IS descnbed
strong analogy to CTL responses to mH antigens and, besides
other common features, also in general require an in vivo
pnming phase However, recently lt was shown that by
employing very potent APC, such as punfied dendntic cells,
pnmary viral antigen specific CTLs could be induced in vitro
{De Bruijn et al, in press) We are currently applymg this
approach to generate a primary anti mH-antigen Τ cell
response in vitro However, in domg so, one should be aware
that, in several modeis, in vitro pnming gave nse to CTLs
recognizmg epitopes distmct from those induced by in vivo
primmg
MHC restriction
CTLs and Th cells definmg mH antigens were observed to be
restncted by MHC class I and class II molecules respectively
The phenomenon of MHC restriction mvolves a Τ cell
receptor (TCR) molecule on the CTL which mteracts with a
tn-molecular complex composed of a MHC class I heavy
chain, a noncovalently bound ß2m hght cham and antigen in
the form of a short, strongly bound peptide Recent expen
ments have indicated that distmct MHC class I alleles contam
distmct sets of peptides26 This observaüon suggests that
MHC restnction involves not only recogmtion of both MHC
and MHC-bound specific peptide, but that the MHC mole-
cule may also be involved at the level of the generation of the
specific (mH) peptide
In mice, MHC class I molecules of all haplotypes (H-2b d k s)
are shown to present (sotne) mH antigens to CTLs Α
predommant restriction by the H-2b haplotype is observed 5
This may not be surprismg smce the majonty of murine mH
antigens have been defined usmg H-2b mice The phenom-
enon that some mouse strains of a given H-2 haplotype are
so-called 'nonresponders', ι e they do not reject skm or
develop CTLs when confronted with an immunogenic mH
antigen, is not well understood This 'Ir-gene effect' has so far
not been observed in man The Ir-gene effect has been
investigated most thoroughly by Simpson et al for the CTL
response to the Η Υ antigen 2 7 In man, Η Υ specific CTLs
have been descnbed restncted by several MHC class I
molecules ( 1 7 1 8 and unpublished observations) Of the CTL
clones which have been used to define autosomal human mH
antigens, many use either HLA-A279 or HLA-B78J5 as
restriction molecules However, at this point in time lt cannot
be excluded that the high frequency of the HLA-A2 allele in
the population or a bias of the mvestigators are responsible
for this apparent preferential MHC restriction
Immuno dominance
Immumzation of mice against multiple mH antigens results in
the generation of CTLs specific for only a hmited number of
so-called 'immunodominant' mH antigens5 For example,
most of the 40 BALB Β mH antigens are capable individually
Human mwor htstocompatibüity antigens 31
of inducing CTL responses when present as Single alloanti-
gens, but do not mduce measurable CTL responses when
C57BL/6 mice are immumzed simultaneously with all
BALB Β mH antigens28 Immunodommant mH antigens
have been descnbed m several modeis mvolvmg multiple
dispanties, and a ranking of more or less dominant antigens
has been suggested (reviewed in 5 ) Smce dommatmg and
dominated antigens must be present on the same lmmumzing
cells, immunodominance IS thought to be regulated by anti-
gen competition at the level of the antigen presenting cells
Though the exact mechamsm remams to be elucidated,
antigen competition would be very well compatible with the
recent view that mH antigen specific CTLs see peptides
bound to MHC class I molecules In humans, the number of
identmed mH antigens is too low to conclude whether
immunodominance in general governs the Τ cell response to
multiple mH antigens Assuming that, as in the mouse, the
human genome has an abundancy of mH loci, some recent
results by our group can at least be called suggestive From
the PBL of three mdividuals, each transplanted across a
multiple (and probably distmct) mH barner, CTL clones
reactive to the same antigen termed HA-1 were obtamed 9
mH antigens and bone marrow
transplantation
Graft versus host disease (GvHD) still forms a major barner
to successful bone marrow graftmg between HLA-identical as
well as HLA-matched donor-recrpient pairs It is beyond the
scope of this review to elaborate on the pathological manifes-
tations of acute and chromc GvHD and the progress made by
clmicians in mimmizing lts comphcations However, two
GvHD nsk factors relevant to understand the impact of mH
antigens m BMT are discussed below
The incidence of GvHD increases with mcreasing genetic
differences between BM donor and recipient Typical in
cidence values are (1) <1% for autologous graftmg and
monozygotic twms, (2) 36% for HLA genotypically identical
siblmgs, (3) 40% for sibhngs shanng one genotypically identi-
cal and one phenotypically identical haplotype of chromo-
some six, and (4) 50-79% for Α, Β, DR matched unrelated
MLC-negative donors 2 9 The contnbution of mH antigens is
lllustrated by the difference between groups 1 and 2, which is
due to dispanties witbin half of the genome, for which siblmgs
are expected to differ Likewise, donor-recipient mcompati-
bihty in group 4 cojnpared to group 2, comprr/es additional
dispanties for mH antigens (total genome), plus MHC hnked
loci on chromosome 6 Within each group, GvHD occurs
more often when female BM is grafted into male recipients,
lllustrating thf effect of an additional incompatibility for the
male specific mH antigen H-Y 1 0
Mature donor Τ cells have been shown to be required for
the development of GvHD, since pretreatment of bone
marrow using Τ cell specific antibodies or by means of
physical Separation almost completely prevents chnical
GvHD The benefits of using Τ cell depleted BM m terms of
graft-survival are reduced by the associated mcreased nsks of
graft faüure, mfection and recurrence of the original dis-
ease30 Thus, the effects of Τ cell depletion and histo-
mcompatibihty stress the reqmrement for mature donor Τ
lymphocytes reactive to the histocompatibihty antigens of the
patient for GvHD to occur
Effector mechanisms in GvHD
mH antigen specific CTLs
The first senes of studies performed in mice to identify the Τ
cell subset responsible for the induction of anti-mmor GvHD
umformly imphcated Lyt2 (CD8) expressing CTL By using
BM inocula completely depleted of L3T4 (CD4) Τ cells,
direct evidence was provided that CTLs on their own were
sufficient to cause lethal GvHD in the B10BR into CBA
multiple mH disparate model31 The notion that CTLs might
not be required nor sufficient for GvHD was first aroused by
Hamilton32 who noticed the presence ot CTLs in the spleens
of BM grafted mice lackmg signs of GvHD Extensive studies
subsequently performed by Korngold and Sprent and
Hamilton, employing additional mH disparate strams of mice,
revealed that dependmg on the genetic background (mclud
ing H-2) and the mH dispanty, either the Lyt2 or the L3T4 or
both Τ cell types could cause GvHD (reviewed in 3 3) Later,
an analogous senes of observations was made in man The
first reports by Tsoi and our own group revealed the presence
of CTLs in the blood of patients undergoing GvHD, which
displayed host-antigen specific MHC class I restncted lysis in
vitro In these initial reports, the presence of host-reactive
CTLs in the blood was found to correlate with the occurrence
of acute 3 4 and chromc7 GvHD, respectively However, in an
extensive recent study this correlation was not confirmed v
Although patients with chromc GvHD tended to develop
higher and more persistent levels of anti-host CTL activity
than those without GvHD, this findmg was not statistically
signmcant In fact, the in vitro protocol used in which
lymphocytes at several dates after BMT were boosted with
pre BMT PBL in vitro, revealed host-antigen specific CTLs m
all 16 patients in at least one point in time
In a very recent study by our group, the role of anti-mmor
CTLs was further elucidated by quantifying the frequency of
CTL precursors (CTLp) in PBL of BM recipients usmg a
hmitmg dilution (LD) assay (de Bueger et al, in press) HLA
identical BMT was found to mduce high frequencies of mH
antigen specific CTLs detectable in the blood dunng the early
phase (25-100 days) of reconstitution However, the number
of CTLp against host antigens showed the same development
in time in all patients (ι e high 25-100 days, falhng in time to
become undetectable after 400 days), irrespective of their
GvHD Status Therefore, the fiequency of recipient-reactive
CTLp in PBL was found not to predict the incidence of
GvHD The same conclusion was recently drawn by Perrault
m a murine GvHD modellf> Usmg a LD assay, frequencies of
CTLp agamst host antigens were measured in 12 strains of
mice after graftmg with mH mismatched BM Spleen cells of
all mice were found to contam high frequencies of host-
reactive CTLs shortly after BMT, whether they developed
moderate acute GvHD or not
It is tempting to conclude from these murine and human
studies that anti-minor CTLs are neither necessary nor suffi-
cient for the development of GvHD However, this hypoth
esis is contradicted by a large body of evidence suggestmg
that CD8+ Τ cells do play a role in mducing GvHD across
mH barriers Notably, GvHD in the same mouse stram
combinations as analyzed by Perrault36 had previously been
shown to be caused by the CD8+ Τ cell subset33 Hence, these
recent LD studies do not negate the role of mH antigen
reactive CTLs in GvHD, but rather question the chmcal value
of in vitro analysis of post-BMT CTLs obtamed from the
peripheral blood Further evidence in man favounng a role of
CD8+ Τ cells m GvHD was provided by a recent study
showmg that the mcidence of GvHD was reduced (without an
mcrease m the recurrence of leukaemia) when HLA-identical
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BM depleted of the CD8 subset of mature Τ cells was used37
In vitro data in support of a role of CTLs in GvHD in man
were provided by Kaminsky et al22 The frequency of
recipient-reactive CTLp present in donor PBL before BMT
was found to predict the seventy of GvHD after BMT
However, lt must be stressed that the donor-recipient paus in
this study were unrelated, HLA-matched, MLC nonreactive
pairs of mdividuals Apparently, the CTLp asssay IS not
sufficiently sensitive to measure sigmficant values before
BMT between HLA-genetically identical mdividuals (de
Bueger et al, in press), whereas the presence of additional
genetic differences in the case of HLA-matched donor-
recipient pairs enables in vitro measurement of unprimed mH
antigen specific CTL responses22 These additional genetic
differences may he in HLA subtypes not detected by typing
or HLA linked loci, as well as in an mcreased number of
incompatible mH loci
Additional effector modeis
The seemingly conlradictory results on the putative correla-
tion between mH antigen reactive CTLs in PBL and GvHD
after BMT may be explained by (1) measurement of the
'wrong' CTL population, or (2) the existence of factors, in
addition to mH antigen specific CTLs, which codetermine the
outcome of HLA identical BMT
Under the first headmg above, the blood may not be the
nght site to monitor those CTLs potentially relevant in
GvHD The observed disappearance of anti-host CTLp in
time in PBL could well be attnbuted to an initial penpheral
expansion followed by redistnbution and migration out of the
blood into the target tissues Whereas this lymphocyte traf-
fickmg was suggested in rodent modeis,38 to date no evidence
Supports a sigmficant lymphocyte homing to the GvHD
affected tissues in man v) Furthermore, the anti host CTL
population quantified in vitio may compnse CTL clones
reactive to all distmct host mH antigens However, some host
mH antigens appear to be more 'dominant' in the mduction
of GvHD than others (see mH antigen specificity of effector
cells) In addition, CTLs reactive to tissue-specific mH anti-
gens may strongly contnbute to the local GvHD phenomena,
whereas the usage of Epstein Barr virus transformed Β lym-
phoblastoid cell lmes (EBV BLCL) or PBL as stimulator
cells allows expansion and detection of only those host-
reactive CTLs which recognize mH antigens on lymphoid cell
types The potential relevance of target tissue specific mH
antigens in GvHD is supported by the finding that in vitro
responses of donor Τ cells to host epidermal cells, but not to
host lymphoid cells, are predictive for the occurrence of
GvHD after HLA-identical BMT 4 0 Also, CTLs specific for
the skm specific munne mH antigen EPA-1 mflict GvHD-hke
tissue destruction when injected in vivo 41
The contnbution of factors other than mH specific CTLs
must be considered too It is very possible that, though no
sigmficant correlation between the presence of CTLs and
GvHD is measured, these anti host CTLs do indeed contnb-
ute to the mduction and/or effector phases of GvHD In
particular, lf CTLs are required but are dependent for their
activity on mteraction with Th cells and soluble factors, they
would not by themselves be sufficient to account for the
development of GvHD The last few years evidence has
accumulated that, in addition to CTLs, host antigen specific
CD4+ Th cells could be relevant in GvHD Van Eis et al
demonstrated that sigmficant Th cell activity in vitro tended
to correlate with chnical acute GvHD 4 2 Mouse strains have
been identified in which the L3T4+ subset alone induced
GvHD, whereas the additional presence of Lyt2+ cells in the
donor inoculum intensified the GvHD reacüons 13 Genetic
analysis of loci encoded withm the munne H-3 and H-4
regions has revealed the existence of separate loci encoding
Th cell and CTL mH epitopes Dispanty for both Th and CTL
epitopes was required to mduce a CTL response in vivo,43
mdicatmg the relevance of Th-CTL cell collaboration in the
anti H-3 and anti H-4 immune response Most recently, an
LD assay was developed to measure the frequency of pre-
transplant donor Th cell precursors against host mH antigens
Prehmmary results on 16 donors of HLA-genotypically iden-
tical BM mdicated that a high frequency of helper Τ cells
might be predictive of subsequent severe acute GvHD 4 4
Since GvHD does not occur m the complete absence of
histocompatibihty differences, it can be anticipated that
somewhere m the cascade of cellular events leading to
GvHD, antigen specific Τ cells must be involved in at least
one phase However, this does not exclude an important
contnbution of antigen nonspecific factors such as lympho-
kines in the development of GvHD Convincmg data were
obtained on the role of TNFa in munne and human GvHD
Antibodies to TNFa could completely prevent lethal GvHD
induced in mH disparate mice 4 5 In a GvHD-predictive assay,
the in vitro GvH reactivity to host skin tissue was found to
correlate with the levels of TNFa and INF7 secreted into the
culture medium46 Also, the GvHD inducing potential of
some mH antigen specific Τ cell clones has been shown to
correlate with the levels of TNFa clones produced in vitro 4 7
Effector cells in the skin
Seeking to define the effector cell type responsible for the
local pathogenesis in the target organs of GvHD, particular
attention has been paid to the skin This is because the
epithehum of the skm is the first and most commonly affected
tissue m acute GvHD and because the infectious complica-
tions which often accompany chromc GvHD predoimnantly
are caused by lesions in the skin The majonty of histopatho-
logical studies of munne and human GvHD-affected skm
after graftmg with unmampulated, mH disparate BM, de-
scnbe a moderate, but certamly not extensive, mononuclear
cell mfiltrate contaming mcreased numbers of CD8 express-
mg cells The common observation of mononuclear cells in
close apposition to necrotizmg basal keratmocytes48 has
strongly suggested that CTL mediated lysis of keratmocytes
might occur However, one recent report denies the role of
CD8+ cells m the pathology of human cutaneous GvHD No
sigmficant difference was observed between the absolute
numbers or ratlos of lymphocyte subsets present in GvHD-
affected compared to unaffected skin in 21 patients after
HLA-identical BMT3 9 Another group of investigators de-
scnbed cell types other than CD8+ CTL in contact with
degenerating epithehal cells in the skm of mice suffering from
anti-minor GvHD 4 9 5() In the first of two consecutive reports a
skin infiltrating cell population, termed large granulär lym-
phocytes, was described to express a natural küler (NK) cell
marker, but none of the Τ cell markers CD4, CD8 or CD3 4'J
In the second report, however, studymg the same B10BR
into CBA minor disparate model, these skm infiltrating cells
were claimed to have a distmct phenotype (1 e NK-marker,
CD3 and CD8 negative but CD4 positive)50 Some of the
differences on the lymphocyte subsets proposed as effector
cells in these histoimmunochemical studies may reldte to the
usage of distmct and more or less well defmed antibodies
Others may reflect the usage of distmct mH disparate combi-
nations of mice as expenmental GvHD modeis The usage of
bone marrow grafts selectively depleted of either the CD4 or
the CD8 Τ cell subset allowed Piguet et al51 to directly show
that Τ cells of the phenotype capable of inducmg GvHD in
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particular mouse strains were indeed always observed in
increased numbers in necrotizing skin.
Recent work by our group has revealed that some mH
antigen specific CTL clones (i.e. αΗ-Y, HA-3, HA-4, HA-6
and HA-7) lysed skin epithelial cells in a MHC class I
restricted, mH antigen specific fashion.52'53 These in vitro data
suggest that at least some mH antigen specific CTL clones
(though obtained from PBL and not from the skin itself) have
the potential to serve a direct effector function in the local
GvHD pathogenesis via CTL-mediated lysis of epithelial
target cells. Furthermore, our preliminary results indicate
that some, though not all, mH antigen specific CD4+ Th cell
clones can be induced to proliferate upon coculture with
intact layers of MHC class 11+ and ICAM-1+ keratinocytes
(de Bueger et al, in press).
Summarizing, both cytotoxic and proliierative Τ cells might
be responsible for the pathogenesis of GvHD. It has been
established in murine modeis that the phenotype of the
effector cells involved locally and systematically is influenced
by the genetic background and the mH barrier involved. Most
importantly, the mere detection of host reactive Τ cells in
lymphatic organs by means of in vitro assays does not ensure
their relevance as effectors in GvHD.
mH antigenic specificity of effector cells
To identify the nature of mH antigens relevant for the
development of GvHD after multiple mH disparate BMT,
most investigators in man and mouse have performed in vitro
analysis of host-reactive Τ cell lines obtained from spieen,
peripheral blood or skin from individuals suffering from
GvHD. Only a few investigators have attempted to 'identify'
the nature of recipient-specific, MHC restricted mH antigens.
In man, we determined the reaction patterns towards a panel
of 100 target cells of 12 out of 160 CTL clones obtained from
five MHC class I restricted, recipient specific CTL lines.7·9
Five distinct patterns of panel recognition were found and
interpreted to define distinct mH antigens. However, since
long-term in vitro culturing of the CTL lines preceeded
limiting dilution and not all clones per patient were analyzed,
no conclusion could be drawn on the relative importance of
these five mH antigens in triggering CTLs in fully mH antigen
disparate BMT. In the mouse, Wettstein et al.28 used a
transplantation barrier consisting of more than 40 known
BALB.C mH loci, and analyzed the specificity of generated
CTL lines on target cells expressing Single (B6.C series of
congenic strains) or several (CBX series of recombinant
inbred (RI) strains) of the immunizing BALB.C mH loci.
From the detection of H-2Kb restricted CTLs with only four
distinct specificities, other than the known BALB.C antigens,
two main conclusions were drawn. First, mH antigens induc-
ing CTL responses after BMT can differ from those defined
by skin gtaft rejection. Secondly, the repertoire of CTLs
triggered by multiple mH disparate BMT, which mimicks best
the Situation encountered in man, can be reactive to only a
limited number of mH antigens.
However, as discussed above, host-reactive Τ cells detect-
able in vitro may be present in GvHD-free animals and
patients.32·35 Thus, the approach used in these studies does
not α priori guarantee that the Τ cell clones studied recognize
'GvHD relevant' mH antigens. This aspect was addressed in a
recent study by Miconnet et al."'1 Seven mH antigen specific Τ
cell clones were generated from spieen cells of GvHD mice,
expanded and analyzed for lymphokine production, mH
antigenic specificity and GvHD-inducing potential upon re-
injection. Three CD4+ Τ cell clones specific for the mH
antigens termed Ag-I and Ag-II, each producing high levels
of TNFa in vitro, induced vigorous GvHD reactions in vivo.
Two other CD4+ Τ cell clones (reactive with a mH antigen
termed III) and a CD8+ cytolytic Τ cell clone (specific for Ag
IV) did not. However, in trying to Interpret these results the
investigators were confronted with the complication of having
two unknown variables, i.e. (1) the specific mH antigens
recognized and (2) the phenotype, lymphokine production,
and proliferative and/or cytotoxic characteristics of the Τ cells
responsible for GvH reactions in vivo. One could conclude
that those mH antigen reactive Τ cells which produce TNFa
are relevant in GvHD; however, one could also argue that Τ
cells specific for the mH antigens I and II, but not for III and
IV are relevant in GvHD.
In conclusion, despite numerous efforts, little Information
is currently available on the number and molecular nature of
the mH antigens governing the GvHD responses induced in
multiple mH antigen disparate BMT. Striving for controllable
GvHD in HLA-identical bone marrow transplantation, it
would be desirable if a limited number of dominant antigens
were involved, as preliminary data in the mouse have
indicated.
Nature of mH antigens
Recently, the general view of the nature of mH antigens has
drastically changed. It is now clear that in contrast to an MHC
antigen which refers to an immunogenic glycoprotein, an mH
antigen does not refer to a Single molecular entity. Instead,
one should make a distinction between the Τ cell epitopes
seen by mH antigen specific CTLs on one hand, and the
intracellular gene products giving rise to them on the other
hand. The huge Steps made in the elucidation of the 'MHC
class I restricted processing pathway'54 have led to the
Suggestion that mH antigen specific CTLs recognize peptides,
derived from intracellular proteins, which are processed and
presented by MHC class I molecules.
mH peptides
Identification
Two main lines of investigation have led to the definition of
the limited number of mH peptides which are known to date.
The first strategy involves the enormous task of sequencing
Stretches of genomic DNA known to include the genes
encoding the mH Τ cell epitope. Subsequent cellular testing
of synthetic peptides generated according to the deduced
protein sequences has resulted in the definition of peptides
recognized by mH antigen specific Τ cell clones.55 Using this
approach CTL clones defining Mta, a maternally transmitted
mitochondrial murine mH antigen, were found to recognize
synthetic peptides corresponding to a polymorphic part of
mitochondrial protein ND-1.56 Hydrophobie peptides of
17-26 amino aeids in length were efficiently recognized;
peptides of 12 amino aeids were moderately well recognized,
whereas shorter Stretches did not sensitize target cells for
recognition by anti-Mta CTL at all. The H-2d restricted
epitopes on three 'tumour negative' (tum-) variants P91, P35
and P198, generated by chemical mutagenesis of P815 cells,
could be mimicked by hydrophobic peptides of 13, 11 and 11
amino aeids, respectively (reviewed in 5 6 ) . These peptides
each differed at one position from their allelic counterparts,
which were not recognized by CTLs.
The second approach to identify mH peptides was de-
veloped by Rammensee and coworkers,26'57 and has since
then been applied by several investigators for purification of
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MHC class I and class II bound peptides. The biochemical
procedure involves the extraction of acid soluble low molec-
ular weight material from cells expressing the Τ cell epitope
of interest. Extraction is done of either the complete pool of
acid soluble peptides present in a cell or, by including an extra
affinity chromatography Step, of only those peptides naturally
bound to MHC.58 Subsequent peptide Separation on a
reverse-phase column by means of HPLC yields fractions
which each can be tested for containing Τ cell epitopes. Using
this approach Rötschke et al. showed that the H-Y, H-2Db
restricted epitope and the H-4b, H-2Kb Τ cell epitope were
present in the low MW fractions (<5000 kD) of acid extracts
of spieen cells, provided these expressed H-Y and H-2Db or
H-4b and H-2Kb, respectively. Although the peptidic nature
of the H-Y and H-4b Τ cell epitopes was indicated by
susceptibility to protease treatment and by size estimation
based on HPLC elution profiles, the amino acid sequences of
the cell surface epitopes of these classical mH antigens are
not available yet.57 Other investigators and our group too
have demonstrated the presence of the HLA-B35 restricted
hm-259 and the HLA-A2 restricted mH epitope HA-2 (de
Bueger et al, in press) in the low MW fraction of antigen
expressing acid-eluted EBV-BLCL.
In summary, hydrophobic synthetic peptides of 9-26 amino
acids long are recognized by MHC class I restricted
CTL specific for a number of murine mH antigens. The
naturally occuring epitopes, seen by murine and human
mH antigen specific CTLs can be isolated from the
restricting MHC molecules by acid elution. However, thus
far the amino acid sequences of these peptides have not been
determined.
Processing and presentation
Little is known thus far on the molecular mechanisms in-
volved in the intracellular generation of MHC class I re-
stricted mH peptides. Those few data available confirm that
mH peptides presumably are products of the recently defmed
MHC class I pathway, analogous to viral and self-peptides.
MHC allele specificity The results by Falk et al26 very
strongly suggest that indeed the H-4b and H-Y protein
fragments mentioned above are selected and presented by
MHC class I molecules. They showed that the H-4b and H-Y
peptides detected in whole cell extracts from H-2b mice were
not present in similar extracts from male and H-4b expressing
H-2d mice, indicating a strong MHC allele dependent effect in
the generation of these two mH epitopes. So far, two exam-
ples are available where mH peptides have been directly
eluted from purified MHC class I molecules. In one, the
H-2Kd restricted turn- mH peptide P198.3 was eluted from
purified H-2Kd molecules.60 Although the sequence of this
natural tumour peptide could not be identified directly by
Edman degradation, a synthetic peptide was identified with
identical HPLC behaviour as the natural peptide, and the
sequence of this synthetic mH peptide was compatible with
the binding profile described for H-2Kd bound self-peptides.58
In the second example the Τ cell epitope of the human mH
antigen HA-2 could be eluted from the purified HLA-A2.1
(de Bueger et al, in press). The HA-2 active HPLC fraction
contained merely nonapeptides expressing a Leu at position 2
and 9, therewith confirming the motif previously described for
HLA-A2.1 bound self-peptides.58 However, all our attempts
to mimick the natural HA-2 peptide by (mixtures of) syn-
thetic peptides, generated according to the measured profile,
were thus far unsuccessful. Therefore, at this stage it cannot
be excluded that the natural HA-2 Τ cell epitope, demon-
strated to be a peptide generated and presented by
HLA.A2.1, does not follow the binding restrictions known for
abundant self-peptides.
Competition An argument in favour of mH peptides follow-
ing the same intracellular route as viral peptides was provided
by Kuzushima.61 It was shown that viral infection reduced a
cell's potential to present mH peptides to class I restricted
anti-minor CTLs. Furthermore, the drug brefeldin A, which
selectively blocks transport of newly synthesized proteins
from the ER, inhibited anti-virus and anti-minor target cell
lysis in a similar fashion.
Transport into ER The mutant cell lines RMA-s and
721.174/T2, with a suspected defect in the Iransport of
cytosolic peptides into the class I secretory pathway,54 have
been analyzed for their ability to generate and present mH
peptides. In one report RMA-s failed lo present mH peptides
to the appropriate MHC class I restricted CTLs.62 However,
this finding was contradicted by a study in which mH antigen
specific CTL clones did recognize RMA-s cells.63 The recent
observation that RMA-s cells, though ineffectively, do pres-
ent endogenous antigens, may account for this observation.64
Because of its 'leaky' phenotype these results with RMA's do
not provide clear insight into the processing requirements of
mH peptides. More straightforward results were obtained
with the human T2 cell line. In contrast to its parental cell line
Tl, it was found to be unable to present the human mH
peptide HA-2 to HLA-A2.1 restricted CTLs. Likewise, T2
failed to process and present antigenic peptides from influ-
enza following viral infection. Yet upon transfection of T2
with the rat ABC transporter cDNAs TAP-1 and TAP-2, the
capacity to process and present both the mH antigen HA-2
and the influenza specific peptide for CTL recognition were
restored (Momburg et al., in press). These results indicate that
peptide import into the ER is required for enabling this mH
peptide to bind class I molecules. Moreover, since the signal
recognition particle-mediated pathway54 is unaffected in T2
cells, the failure to present HA-2 indicates this mH peptide
may not represent a signal peptide.
mH proteins
The use of transfection modeis has revealed that proteins in
all cellular compartments and of viral, foreign as well as self-
origin can in principle give rise to class I associated CTL
epitopes. Rammensee et al.65 elegantly illustrated the degen-
eracy of intracellular localization in the ß-galactosidase
model by generating transfectants producing either a glycosy-
lated transmembrane, a cytosolic or a secreted form of the
protein. All three types of transfectants presented identical
peptides to H-2Ld restricted CTL clones. The indicated
irrelevance of glycosylation, intracellular destination and
presence of signal sequences of proteins for the generation of
MHC class I restricted peptides had previously been demon-
strated using the influenza virus model.66 In addition, it has
become evident that proteins do not have to be newly
synthesized nor do they need to be of endogenous origin.
Native ovalbumin, when introduced directly into the cyto-
plasm, was shown to be recognized by H-2b restricted, OVA-
specific CTLs.67
Therefore, of the two criteria used to initially describe
murine mH antigens, one, the recognition by MHC class I
restricted CTLs, appears to be met by many intracellular
proteins. Which intracellular proteins would in principle have
the potential to meet the second classical biological criterion
of inducing skin graft rejection remains to be determined.
Classical mH proteins
Of the classical mH gene products, defined by skin-graft
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rejection between H-2 identical congenic strains of mice, only
very few have been formally defined. The 12 kD protein ß2m
was found to be encoded in the H-3 region on chromosome
12.19 This protein was classified as a mH antigen since it
induces H-2 restricted CTL responses after in vivo priming,
even though its potenlial to induce skin graft rejection is
unclear. However, ß2m as a secreted 12 kD cell surface
molecule may not be representative of mH proteins. The
three known murine alleles of ß2m are recognized as integral
subunits of the MHC class I cell surface complex and do not
require processing or degradation for recognition by ß2m
specific CTLs.68'69 It has been proposed that its behaviour as a
mH antigen reflects differential binding of (mH) peptides by
the distinct ß2m alleles,69 although this remains to be
proven.
Α second identified mH protein is the mitochondrial trans-
membrane protein ND-1. This protein exists in four allelic
forms differing by Single amino acids in the hydrophobic
N-terminal part of the protein, and seems to give rise to
epitopes recognized by Mta-specific CTLs.56 The function of
this ND-1 protein remains elusive; it is suggestive that no
functional differences could be detected between carriers of
the four distinct allelic forms of the protein.
The proteins giving rise to turn— peptides have not been
identified. Given the fact that the sequences of the peptides
recognized by turn- specific CTLs were identified (see mH
peptides), the identity of their proteins was expected to be
found within protein databases. However, this was not the
case. Boon and coworkers have advanced two explanations
for this inability to find the protein source of these peptides.
Either turn— peptides originate from as yet unidentified
cellular proteins or, alternatively, are directly encoded by
small pieces of promotorless DNA, so-called 'peptons', and
thus would not result from proteolysis of translated functional
proteins. This new and provoking concept so far has not been
supported by experimental evidence.70
In summary, the ubiquitous glycoprotein ß2m, involved in
cell surface transport and stabilization of MHC class I mole-
cules, and the mitochondrial transmembrane protein ND-1 of
unknown function, constitute the only two proteins identified
as giving rise to cell surface epitopes recognized by mH
antigen specific CTLs.
'New' mH proteins
Viral (regulated) proteins Α concept formulated in 1966 was
that mH proteins might be encoded or regulated by retroviral
genes.71 This notion was substantiated by Wettstein72 who
described close linkage between ectotropic and xenotropic
retroviral sequences and B6 mH loci. However, it could not
be excluded that the observed linkage could result from
random insertion of retroviral as well as mH loci in the
genome. In an attempt to provide direct evidence, Colombo73
inserted Moloney murine leukemia viral (Mulv) genes into
BALB/c, C57B/6 and 129 strain embryos to generate so-
called 'Mov co-isogenic' strains. Skin grafts from these Mov
strains of mice were rejected by their co-isogenic partners,
differing only for the inserted viral gene. The induced H-2b
restricted CTLs were shown to recognize a Mulv-derived
product since Mulv- and Rauscher-virus infected background
strain target cells were lysed. With these results, Colombo
was the first to provide direct evidence that retroviral se-
quences, when introduced into the genome can result in cell
surface epitopes inducing skin graft rejection and class I
restricted CTL responses.
In man, virtually nothing is known about retroviral inser-
tions in the genome. At this point the hypothesis that
germline inserted (retro-) viral genes encode or regulate
(some) mH proteins remains open.
Self-proteins Α second general hypothesis held by many
investigators in the field of mH antigens is that polymorphic
(parts of) intracellular 'seif proteins could represent mH
transplantation barriers. The murine mH protein ß2m repre-
sents such a polymorphic self-protein. However, as discussed
above, ß2m may be an exception since it is recognized as a
whole cell surface protein instead of as a processed peptide.
To test the hypothesis that a polymorphic self-protein could
act as a transplantation barrier, Speiser et al.74 made use of
the known polymorphism of the murine myxovirus resistance
nuclear protein MX. Indeed, skin grafts from MX protein-
expressing BALB.c mice were rejected by MX-negative
BALB.c congenic partners. Furthermore, injection of MX-
expressing spieen cells into MX-negative BALB.c congenic
mice resulted in MX antigen specific CTL after in vitro
boosting. Notably, cell surface expression of the MX protein
in MX+ mice was shown to depend on Stimulation with
IFN-γ.
Thus, the creation of new mH gene products has indicated
that viral as well as self-proteins can fit the description of mH
transplantation proteins. Proteins of (retro)viral, foreign or
self-origin located in either ER, cytosol or any other organelle
can give rise to peptides immunogenic to class I restricted
CTL and can represent transplantation barriers. The research
of the coming years will have to prove how many and which
of these peptides are brought to the cell surface and which
actually do represent barriers in transplantation.
Immune surveillance in healthy
individuals
Shaping the Τ cell repertoire
In the thymus, immature bone marrow derived thymocytes
undergo Τ cell receptor (TCR) gene rearrangements, matura-
tion and subsequent selection. This selection process must
ensure that self-reactive, potentially autoaggressive, Τ cells
do not reach the periphery (negative selection). At the same
time it must ensure that functionally relevant Τ cells, i.e. seif
MHC restricted Τ cells specific for foreign antigens, are
allowed to populate the peripheral lymphoid Organs (positive
selection) (reviewed in 7 5 ) . The now established view that
mature Τ ceils recognize peptides presented in association
with MHC class I and class II molecules has led to the notion
that the interaction with peptide/MHC complexes might in a
similar fashion regulate the development of maturing
thymocytes.
According to the current model, all self-peptides including
seif mH peptides, produced and presented in sufficient num-
bers by seif MHC molecules, will induce negative selection of
the specific Τ cells. The repertoire of seif MHC restricted Τ
cells which is left after negative selection to respond to
pathogenic foreign antigens is therefore dependent on the
composition of the set of self-peptides present. There are
several examples where modification of the TCR repertoire
as a result of expression of a certain mH or self-peptide could
be demonstrated either by a skewed Vß usage of the remain-
ing Τ cells,76 or by functional deficits in the immune response
to foreign antigen.77 Mice expressing certain alleles of the
murine mH antigen Mls are found to lack subsets of Τ cells
using particular TCR genes. However, Mls is not considered a
classical mH antigen since Mls-reactive Τ cells are found at
very high precursor frequencies and are restricted by more
than one MHC class II allele. For most classical mH antigens
it is not known whether they induce Τ cell subsets which
express only particular Vß genes. Preliminary results from
36 Μ de Bueger and Ε Goulmy
our laboratory have mdicated that distmct CTL clones spe-
cific for H-Y use distinct Vß genes, even when a H-Y peptide
in the context of the same MHC class I molecule was seen
(Kammsky et al, unpublished observations) By contrast,
several CTL clones denved from different individuals, all
specific for the mH antigen HA-1, all seemed to use an
identical Vß, but distmct Va and J segments (pers comm)
However, even lf Τ cell responses to classical mH peptides
generally involve the predominant usage of certam TCR
genes, one would not expect that negative selection of these Τ
cells would change the penpheral TCR repertoire m mH
expressmg individuals to a measurable extent because of the
low precursor frequencies of mH antigen reactive Τ cell
populations in unpnmed individuals Moreover, not all 'blmd
Spots' in the TCR repertoire, created as a result of expression
of seif mH antigens, functionally abohsh the abihty of the
individual to mount a Τ cell response to foreign antigens
That the immune System can mdeed cope with such blind
spots was lllustrated by an expenment of Rammensee et al
Whereas the anti H-Y response in Mls-la negative mice was
mamly mediated by Vß6+ Τ cells, this response was not
abrogated in MlS-ld positive mice (which lack penpheral
Vß6+ Τ cells) but, instead, was mediated by Τ cells carrymg
distinct TCRs 7 8
In contrast to the potentially negative effect of inducmg
blind spots, expression of seif mH antigens may contnbute in
a positive fashion to the shaping of the Τ cell repertoire The
presence of a distmct set of polymorphic mH peptides in each
individual might allow a distinct fraction of seif MHC re-
stncted Τ cells to mature and contnbute to the diversity of the
TCR repertoire withm the species Diversity of the TCR
repertoire in lts turn would positively influence the survival of
the species since a broader ränge of pathogenic antigens can
be recognized
Tumour surveillance
In a healthy individual all Τ cells reactive to seif mH peptides
presented by seif MHC molecules will be deleted in the
thymus (see above) or will be tolenzed by means of a
penpheral mechamsm However, potentially autoreactive Τ
cells specific for peptides denved from polymorphic self-
protems which are, under physiological conditions, not gen-
erated, are allowed to mature and can be found in penpheral
blood79 Therefore, lt IS highly hkely that mature antigen
specific Τ cells will be present to recogmze mH peptides
which become newly generated or overexpressed in the
course of hfe For example, changes in the mtracellular
protem content as a result of mduced transcnption of onco
genes in a developmg tumour cell, might result in new mH
peptides presented by the cell's MHC molecules The efficacy
of this presently theoretical form of immune surveillance is
unclear
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